Sanofi-Aventis’ €1.8bn ($2.6bn) offer for Czech generics firm Zentiva has been unanimously accepted by the latter firm’s board after four months of wrangling that has seen the bid increase by 9.5 per cent.
in-PharmaTechnologist.com's latest round-up of developments in pharmaceutical manufacturing features news of the world’s “biggest pharmaceutical allergen production unit”, Lentigen’s relocation and a cytotoxic robot.
APP Pharmaceuticals has bought additional facilities at a site in Grand Island, New York seizing the opportunity created by Astellas Manufacturing’s decision to shift production of its dermatitis drug Protopic to Japan.
Pharmaceutical major Bristol-Myers Squibb has signed another deal with outsourcing specialist Accenture, this time tapping the firm for IT and financial support services via a 10-year contract worth $550m.
Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector, with around 1,500 staff and an annual turnover of €180m.